🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Myelofibrosis
Clinical trial register · United States · industry-sponsored

Myelofibrosis Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 14 Florida 11 Arizona 6 Alabama 6 Colorado 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Karyopharm Therapeutics Inc3 Geron Corporation2 Takeda1 Aspera Biomedicines, Inc.1 Celgene1
State
California14 Florida11 Arizona6 Alabama6 Colorado6
All 29 states
Target enrolment
to
19 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-02
Recruiting
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
NCT07250646Secondary AML, Myelofibrosis
Aspera Biomedicines, Inc.
Phase 1
28
California
2026-05-21
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Kartos Therapeutics, Inc.
Phase 3
600
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Iowa
2024-06-03
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Merck Sharp & Dohme LLC
Phase 3
400
Michigan, North Carolina, Ohio, Pennsylvania
2024-05-23
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Karyopharm Therapeutics Inc
Phase 2
58
California, Maryland, New York, North Carolina, Ohio, Texas, Utah
2024-04-22
Recruiting
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
NCT05423691Myelofibrosis
Cellenkos, Inc.
Phase 1
24
California, New York, Texas
2022-12-27
Recruiting
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
NCT05488548Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Epigenetix, Inc.
Phase 1
75
Arizona, Florida, Massachusetts, Minnesota, Texas, Washington
2022-12-21
Recruiting
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Telios Pharma, Inc.
Phase 1/2
70
Alabama, Ohio, Texas
2022-06-09
Recruiting
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Disc Medicine, Inc
Phase 1/2
150
Arizona, California, Colorado, Florida, Georgia, Michigan, Minnesota, Missouri
2022-06-06
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
NCT05371964Myelofibrosis
Geron Corporation
Phase 1
30
California, Florida, New York, Washington
2022-05-04
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
NCT04679870Myelofibrosis
Galecto Biotech AB
Phase 2
21
Texas
2021-06-09
Active, closed
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156Myelofibrosis
Geron Corporation
Phase 3
327
California, Connecticut, Florida, Kentucky, New York, North Carolina, Ohio, South Dakota
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2021-04-09
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
Bristol-Myers Squibb
Phase 1/2
216
California, Florida, Louisiana, Massachusetts, Michigan, New Jersey, North Carolina, Pennsylvania
2021-03-22
Active, closed
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04562870Myelofibrosis
Karyopharm Therapeutics Inc
Phase 2
112
California, Colorado, Illinois, Texas
2021-03-17
Active, closed
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT04562389Myelofibrosis
Karyopharm Therapeutics Inc
Phase 3
353
Alabama, California, Colorado, Connecticut, District of Columbia, Kentucky, Maryland, Michigan
2021-03-11
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Celgene
Phase 3
313
California, Florida, Illinois, Kentucky, Michigan, Missouri, New Jersey, New York
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Alabama, Colorado, Florida, Georgia, Iowa, Missouri, New Jersey, New York
2021-02-23
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198Myelofibrosis
Sumitomo Pharma America, Inc.
Phase 1/2
240
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2019-12-16
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/myelofibrosis

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.